MET and pancreatic neoplasm: Similarly, Zheng et al., showed that the co-administration of c-MET-targeted CAR-M with gemcitabine or irinotecan amplified antitumour effects in pancreatic cancer models (100), suggesting that certain chemotherapeutics may remodel the TME in ways that enhance macrophage infiltration and persistence.